Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887045 | 0.83 | KDM4E (0.45) | HTR6BCHE | |
| SCHEMBL2992891 | 0.81 | CYP2C19 (0.40) | HTR6BCHE | |
| SCHEMBL2887000 | 0.80 | MEN1 (0.60) | HTR6BCHE | |
| SCHEMBL3045523 | 0.78 | HTR6 (0.49) | HTR6 | |
| SCHEMBL17927509 | 0.76 | HTR6 (0.71) | HTR6BCHE | |
| SCHEMBL17782546 | 0.75 | HTR6 (0.57) | HTR6 | |
| SCHEMBL20492708 | 0.74 | HTR6 (0.45) | HTR6BCHE | |
| SCHEMBL23899503 | 0.74 | L3MBTL1 (0.40) | — | |
| SCHEMBL20492585 | 0.73 | ALDH3A1 (0.41) | HTR6BCHE | |
| SCHEMBL13302231 | 0.72 | HTR6 (0.51) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060293251-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-7129220-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR6 100/4885BCHE 1539/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR6 100/4885BCHE 1539/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | HTR6 100/4885BCHE 1539/4885 |
| US-20060293251-A1 | Substituted indazole-O-glucosides | GPR119, PYGL, GYS2 | HTR6 946/4885BCHE 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.